바이오인

Market and Technology Analysis : Prognostic vs. Predictive Biomarkers Landscape

Not all biomarkers are the same. Learn about the differences between these two important classes.

Enal Razvi, Ph.D.

The of this GEN Market & Tech Analysis report is to provide an update on the prognostic and predictive biomarkers market landscape.

Highlights:

GEN explores in this report the segmentation of prognostic versus predictive biomarkers; this distinction is important as it underlines their clinical potential. The deployment of personalized medicine in oncology and beyond requires a precise understanding of disease progression as well as molecular targeting of therapies in order to “interrogate” the molecular lesion-prognostic and predictive biomarkers have the power to effect these two functions, respectively. Indeed, there are a large number of putative biomarkers postulated in the literature but very few have successfully been utilized in the clinic-if personalized medicine is to expand and scale across therapeutic classes its important for many more biomarkers to emanate and find clinical utility. In the future, we believe that other classes of biomarkers such as circulating biomarkers, microRNAs, as well as epigenetic modifications may serve to broaden the repertoire of prognostic and predictive biomarkers.

☞ 자세한 내용은 첨부파일을 이용하시기 바랍니다.